

Literatura

1. Aapro M, Scherhag A, Burger HU. Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. *Br J Cancer* 2008; 99: p. 14-22.
2. Aapro MS, Link B: September 2007 Update on EORTC Guidelines and Anemia Management with Erythropoiesis-Stimulating Agents. *The Oncologist* 2008;13(suppl 3): 33-36
3. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. *J Thromb Haemost* 2004; 2: 899-909.
4. Abstracts from the Novo Nordisk Special Symposium at the XVIII ISTH Congress, Paris, 2001.
5. *Acta Medica Croatica*, 2005, Vol. 59, Supplement 1, Zagreb.
6. Akingbola OA, Custer JR, Bunchman TE, et al. Management of severe anemia without transfusion in a pediatric Jehovah's Witness patient. *Crit Care Med* 1994; 22(3): 524-528.
7. Aldouri M. The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophilic patients. *Pathophysiol Haemost Thromb* 2002; 32(Suppl 1): 41-46.
8. Amaral JF. Laparoscopic cholecystectomy in 200 consecutive patients using an ultrasonically activated scalpel. *Surg Laparosc Endosc* 1997; 5(4): 255-262.
9. Anderson KC, Ness PM. Scientific basis of transfusion medicine: implications for clinical practice. Second Edition. Philadelphia, W. B. Saunders 2000.
10. Atabek U, Alveraz R, Pello MJ, et al. Erythropoietin accelerates hematocrit recovery in post-surgical anemia. *Am Surg* 1995; 61(1): 74-77.
11. Auerbach M, Anemia management - role of intravenous iron. *Transfusion Alternatives in Transfusion Medicine* 2009; Volume 11(Suppl. 1): 3.
12. Auerbach M, Ballard H, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. *J Clin Oncol* 2004; 22: 1301-1307.
13. Auerbach M, Winchester J, Wahab A, et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. *Am J Kidney Dis* 1998; 31: 81-86.
14. Baigorri F, Russel JA. Oxygen delivery in critical illness. *Crit Care Clin* 1 October 1996; 12(4): 971-994.
15. Bastit L, Vandebroek A et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. *J Clin Oncol* 2008 Apr 1; 26(10): 1611-1618.
16. Bauer J. Léčba intracerebrálního krvácení - skepse nebo optimizmus? *Neurol. Prax.* 2006; 6: 328-330.
17. Beguin Y, Maertens J, et al. Darbepoetin-alfa and I.V. iron administration after autologous hematopoietic stem cell transplantation: a prospective randomized multicenter trial. *Blood* 2008; 112(11): 54.
18. Bennett CL, Silver SM et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. *JAMA* 2008 Feb 27; 299(8): 914-924.
19. Bennett-Guerrero E, Veldman TH, Doctor A, et al. Evolution of adverse changes in stored RBCs. *Proc Natl Acad Sci USA* 2007;104: p. 17063-17068.
20. Beris P, et al. Perioperative anaemia management: consensus statement on the role of intravenous iron. *British Journal of Anaesthesia*, doi:10.1093/bja/aen054. *BJA. Advance Access published online on March 27, 2008.*
21. Bessho M, Hirashima K, Asano S, et al. Multi-center Study Group. Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. *Eur J Haematol* 1997; 58(4): 265-272.
22. Bilchik AJ, Sarantou T, Wardlaw JC, Ramming KP. Cryosurgery causes a profound reduction in tumor markers in hepatoma and non-

- colorectal hepatic metastases. *Am Surg* 1997; 63(9): 796-800.
23. Biogenics pipeline. Erythropoietin [online]. Dostupné na www.biogenicspipeline.com/epo/epo.
 24. Bisbe E, et al. Prevalence of Preoperative Anemia and Hematinic Deficiencies: Results. *Transfusion Alter Transfusion Med.* 2008; 10(4): 166-173.
 25. Blajchman MA, Goldman M. Bacterial contamination of platelet concentrates: incidence, significance, and prevention. *Semin Hematol* 2001 Oct; 38(4, Suppl 11): 20-26.
 26. Bloodless Surgery, International Symposium, Paris, February 1996. Paris, France: Arnette-Blackwell, 1997.
 27. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. *Eur J Cancer* 2004; 40(15): p. 2201-2216.
 28. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. *Eur J Cancer* 2007; 43(2): p. 258-270.
 29. Brejcha M, Gumulec J, Klodová D, Wróbel M. Diagnostika a léčba anémie u onkologických pacientů. Doporučení pro klinickou praxi. *Nový Jičín: Onkologické centrum J. G. Mendela*, 6/2006. Dostupné na <http://www.onkologickecentrum.cz>.
 30. Buemi M, Caccamo C, Nostro L, et al. Brain and cancer: The protective role of erythropoietin. *Med Res Rev* 2005; 25(2): p. 245-259.
 31. Building of Blood System for the 21st Century, Appendix, Medical Alternatives to Blood Transfusions, 1997 November, 3-4.
 32. Burns DL, et al. Parenteral iron dextran therapy: a review. *Nutrition* 1995; 11: 163-168.
 33. Canadian Red Cross Pleads Guilty to Distributing HIV-, Hepatitis C-Contaminated Blood in 1980s. *AP/Las Vegas Sun*, 5/30.
 34. Centers for Disease Control and Prevention. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues and semen for evidence of hepatitis B and hepatitis C. *MMWR - Morbidity & Mortality Weekly Report* 1991; 40(RR-4): 1-17.
 35. Chen RH, Frazier OH, Cooley DA. Antifibrinolytic therapy in cardiac surgery. *Tex Heart Inst J* 1995; 22(3): 211-215.
 36. Chernow B. Blood conservation a critical care imperative. *Crit Care Med* 1991; 19(3): 313-314.
 37. Collins CD, Jackson JE. Pelvic arterial embolization following hysterectomy and bilateral internal iliac artery ligation for intractable primary postpartum haemorrhage. *Clin Radiol* 1995; 50: 710-714.
 38. Connor JP, Morris PC, Alagoz T, Anderson B, Bottles K, Buller RE. Intraoperative autologous blood collection and autotransfusion in the surgical management of early cancers of the uterine cervix. *Obstet Gynecol* 1995; 86: 373-378.
 39. Cooley DA. Conservation of blood during cardiovascular surgery. *Am J Surg* 1995; 170(6A Suppl): 53S-59S.
 40. Corwin HL, Carson JL. Blood Transfusion - When Is More Really Less? *N Engl J Med* 2007; 356: 1667-1669.
 41. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and Safety of Epoetin Alfa in Critically Ill Patients. *N Engl J Med* 2007; 357: 965-976.
 42. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient. *JAMA* 2002; 288: 2827-2835.
 43. Corwin HL, Parsonnet KC, Gettinger A. RBC transfusion in the ICU. Is there reason? *Chest* 1995; 108(3): 767-771.
 44. Critchley J, Dundar Y. Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review. *Transfusion Altern Transfusion Med* 2007; 9: 8-36.
 45. Cuenca J, et al. Patients with pertrochanteric hip fracture may benefit from preoperative intravenous iron therapy: a pilot study. *Transfusion.* 2004 Oct; 44(10): 1447-1452.
 46. Czinn EA, Chediak JR. Coagulation and hemostasis. In: Salem MR, editor. *Blood Conservation in the Surgical Patient*. Baltimore: Williams & Wilkins 1996; 45-78.
 47. Dager EV. Reversal of elevated International Normalised Ratios and Bleeding with Lowe-Dose Recombinant Activated Factor VII in Patients Receiving Warfarin. *Pharmacotherapy*; 2006; 26(8): 1091-1098.
 48. Dahl NV, Henry DH et al. Thrombosis with Erythropoietic Stimulating Agents - Does Iron-Deficient Erythropoiesis Play a Role? *Seminars in Dialysis*, Volume 21, Issue 3, 210-211, Journal compilation © 2008 Blackwell Publishing.
 49. DeMeester SR, Marsh EE, Gerkin TM, et al. Immediate use of recombinant erythropoietin in a Jehovah's Witness following major blunt trauma. *Contemp Surg* 1994; 45: 228-232.
 50. Dietrich W. Aprotinin: 1 year on. *Curr Opin Anaesthesiol* 2009; 22:121-127.
 51. Diez-Lobo AI, et al. Preoperative intravenous iron administration corrects anemia and reduces transfusion requirement in women undergoing abdominal hysterectomy. *Transfusion Alternatives in Transfusion Medicine* 2007; Volume 9, Issue 2: 114-119.
 52. Douglas JT, Shaw J. High-dose desmopres-

- sin in bleeding disorders. *Eur J Anaesthesiol* 1997, Mar 14; (Suppl 14): v-vi.
53. Drife J. Management of primary postpartum haemorrhage. *Br J Obstet Gynaecol* 1997; 104(3): 275-277.
 54. Du X, Williams DA. Interleukin-11: review of molecular, cell biology, and clinical use. *Blood* 1997; 89(11): 3897-3908.
 55. Duke University Medical Center. Banked Blood Loses Ability To Deliver Oxygen To Tissues Almost Immediately. 2007, October 11.
 56. Erhardtsen E, et al. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. *Blood Coagulation and Fibrinolysis* 1998; 9: 741-748.
 57. Eschbach JW, et al. Correction of the anemia of endstage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. *N Engl J Med* 1978; 316: 73-78.
 58. Estioko MR, Litwak RS, Rand JH. Reoperation, emergency and urgent open cardiac surgery in Jehovah's Witnesses. *Chest* 1992; 102(1): 50-53.
 59. European Medicines Agency. European Public Assessment Reports (EPAR) for authorised medicinal products for human use [on line]. Dostupné na www.emea.europa.eu/htms/human/epar/a.htm.
 60. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycolconjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. *N Engl J Med* 1997; 336(6): 404-409.
 61. Fergusson DA, Hébert PC, Mazer D, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. *N Engl J Med* 2008;358: 2319-2331.
 62. Ferzli GS, Hurwitz JB, Fiorillo MA, et al. Laparoscopic splenectomy in a Jehovah's Witness with profound anemia. *Surg Endosc* 1997; 11(8): 850-851.
 63. First European Congress on Bloodless Health Care, May 11 and 12, 2000, Geneva, Switzerland.
 64. Ford PA. Blood Management and Conservation. Center for Bloodless Medicine and Surgery, Pennsylvania Hospital, Philadelphia. Pennsylvania 2007, May 22.
 65. Friederich P, Henny C, Messelink E, Geerdink M, Keller T, Kurth K, Büller H, Levi M. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. *The Lancet* 2003; 361: 201-205.
 66. Gál R, Čundrle I, Stibor B. Krevní ztráta při radikální cystektomii hrazená metodou akutní normovolemické hemodiluce - kazuistika. *Anest. Neodkl. Péče* 2001; 12(4): 176-177.
 67. García-Erce JA, Cuenca J, Solano VM. Predictive factors for transfusion requirements in patients over 65 years old with subcapital hip fracture. *Med Clin (Barc)* 2003; 120(5): p. 161-166.
 68. García-Erce JA, et al. Perioperative intravenous iron preserves iron stores and may hasten the recovery from post-operative anaemia after knee replacement surgery. *Transfus Med* 2006; 16: 335-341.
 69. García-Erce JA, et al. Perioperative stimulation of erythropoiesis with intravenous iron and erythropoietin reduces transfusion requirements in patients with hip fracture. A prospective observational study. *Vox Sang* 2005 May; 88(4): 235-243.
 70. García-Erce JA, et al. Preoperative iron sucrose for anemia outpatients awaiting surgery. A pilot study (abstract). *Transfus Altern Transfus Med* 2006; 8 (suppl): 82-83.
 71. García-Erce JA, Manuel Solano V, Cuenca J, Ortega P. Preoperative hemoglobin as the only predictive factor of transfusional needs in knee arthroplasty. *Rev Esp Anestesiol Reanim.* 2002; 49(5): p. 254-260.
 72. Glaspy JA, Charu V et al.: Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms. *Cancer.* 2009 Mar 1;115(5):1121-1131.
 73. Glaspy JA: Erythropoietin in Cancer Patients. *Annual Review of Medicine*, February 2009, Vol. 60, Pages 181-192.
 74. Glaspy JA: Expert Opin Emerg Drugs. The development of erythropoietic agents in oncology. 2005 Aug;10(3): 553-567.
 75. Gonzalez-Porras JR, Colado E, Conde MP, et al. An individualized pre-operative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty. *Transfus Med.* 2009; 19(1): p. 35-42.
 76. Goodnough LT, et al. Detection, evaluation, and management of anemia in the elective surgical patient. *Anesth Analg* 2005; 101:1858-1861.
 77. Goodnough LT, et al. Erythropoiesis in patients stimulated with erythropoietin: the relevance of stored iron. *Vox Sang* 1998, 75 (2): 128-133.
 78. Greenberg PL: Erythropoiesis-Stimulating Agent (ESA) Treatment of MDS: Controversies and Perspectives. September 1, 2007.

- www.hematology.org/Publications/Hematologist/2007/1115.aspx
79. Grobbelaar AO, Horlock N, Gault DT. Gorlin's syndrome: the role of the carbon dioxide laser in patient management. *Ann Plast Surg* 1997; 39(4): 366-373.
 80. Harrison's Principles of Internal Medicine, edited by Eugene Braunwald, et. al. Philadelphia: McGraw-Hill, 2001.
 81. Heapová P, et al. Odběr autotransfuze a akutní normovolemická hemodiluce na jednotce intenzivní péče. *Urolog. pro Praxi* 2006; 3:137-138.
 82. Hedenus M, Birgegard G, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patient with lymphoproliferative malignancies: a randomized multicenter study. *Leukemia*. 2007; 21:627-632
 83. Hedner U, Ezban M. Tissue Factor and Factor VIIa as Therapeutic Targets in Disorders of Hemostasis. *Annu Rev Med*. 2008; 59: 29-41.
 84. Hedner Ulla. Mechanism of action, development and clinical experience of recombinant FVIIa. *J Biotechnol* 5 August 2006; 124(4): 747-757.
 85. Hedner Ulla. Recombinant factor VIIa: its background, development and clinical use. *Curr Opin Hematol* May 2007; 14 (3): 225-229
 86. Hendriks H G, Maijer K, deWolf JT, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. *Transplantation* 2001; 71: 402-405.
 87. Henry DH, Spivak JL. Erythropoietin and Oncology. In: NATA Textbook - TAB. Transfusion Medicine and Alternatives to Blood Transfusion, 2000 [on line]. Dostupné na www.nataonline.com/CONNATTex.php3.
 88. Hillman RS, Ault KA. Hematology in clinical practice: a guide to diagnosis and management. New York: Mc Graw-Hill Medical Pub. Division 2002.
 89. Holcomb JB, Pusateri AE, Hess JR, et al. Implications of new dry fibrin sealant technology for trauma surgery. *Surg Clin North Am* 1997; 77(4): 943-952.
 90. Holub Z, Feyereisl J, Kabelík L, Rittstein T. Úspěšná léčba závažného poporodního krvácení po císařském řezu pomocí rekombinantního aktivovaného faktoru VII. *Čes. Gynek*. 2005; 70(2): 144-148.
 91. Implementation Handbook for the Convention on the Rights of the Child, New York: UNICEF 1998.
 92. Ingerslev J, et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. *Haemostasis* 1996; 26 (Suppl. 1): 118-123.
 93. Ingram DA, Forman MB, Murray JJ. Activation of complement by fluosol attributable to the pluronic detergent micelle structure. *J Cardiovasc Pharmacol* 1993; 22: 456-461.
 94. Kasirajan, K, Cornu-Labat, G, Mehta, T, et al. Intracavitary packing with oxidized regenerated cellulose: a therapeutic option following major liver injury. *Contemp Surg* 1998; 52: 123-127.
 95. KDOQI. Clinical Practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. *Am J Kidney Dis* 2006, 47: Suppl.3.
 96. Kendall J, Reeves B, Clancy M. Point of care testing: randomised controlled trial of clinical outcome. *BMJ* 1998, Apr; 4; 316(7137): 1052-1056.
 97. Kenet G, et al. 1999. Treatment of traumatic bleeding with recombinant factor VIIa. *Lancet* 354:1879.
 98. Khorana AA, Francis CW et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. *Arch Intern Med*. 2008 Nov 24;168(21):2377-2381.
 99. Kiefmann R, Rifkind JM et al.: Red blood cells induce hypoxic lung inflammation. *Blood*, May 15, 2008; 111(10): 5205 - 5214.
 100. Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. *Transfus Med Rev* 2003; 17: 120-162.
 101. Klowden AJ, Salem MR, Fahmy NR, et al. Deliberate hypotension. In: Salem MR, editor. *Blood Conservation in the Surgical Patient*. Baltimore: Williams &Wilkins 1996; 189-251.
 102. Koch CG, Li L et al. Duration of red-cell storage and complication after cardiac surgery. *N Engl J Med* 2008; 358: 1229-1239.
 103. Kondziolka D, Flickinger JC, Bissonette DJ, et al. Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. *Neurosurgery* 1997; 41: 776-785.
 104. Kristensen J, Killander A, Hippe E, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. *Haemostasis* 1996; 26(Suppl 1): 159-164.
 105. Kubba AK, Palmer KR. Role of endoscopic injection therapy in the treatment of bleeding peptic ulcer. *Br J Surg* 1996; 83(4): 461-468.
 106. Lasota Z, et al. Substituční hemoterapie. Doporučení pro klinickou praxi, vydáno 2. května 2006.
 107. Lifton R, Bennett JM. Clinical use of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in neutropenia associated with malignancy. *Hematol Oncol Clin N Am* 1996; 10(4): 825-839.

108. Lodge JPA., Jonas S, Jones RM, et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. *Liver Transplant* 2005; 11: 973-979.
109. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. *Eur J Cancer* 2004; 40(15): 2293-2306.
110. Mair H, Kaczmarek I, Oberhoffer M, et al. Surgicel Nu-Knit hemostat for bleeding control of fragile sternum. *J Thorac Cardiovasc Surg* 2005; 130: 605-606.
111. Management of Anaesthesia for Jehovah's Witnesses. The Association of Anaesthetists of Great Britain and Ireland, 1999.
112. Maniatis A. How we establish the correct use of blood and IV iron in the hospital setting? Perspectives in IV iron. *International Series of Meetings*, January 2008; 14-15.
113. Maniatis A. Intravenous iron as an alternative to blood transfusion. *Fereport* 2007: 4-5.
114. Mann MC, Votto J, Kambe J, et al. Management of the severely anemic patient who refuses transfusion: lessons learned during the care of the Jehovah's Witness. *Ann Intern Med* 1992; 117(12): 1042-1048.
115. Martini A, et al. Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. *Lancet* 1994; 344: 1052-1054.
116. Martinowitz U, et al. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. *J Thromb Haemost* 2005; 3: 640-648.
117. Martinowitz U, Kenet G, Segal E, et al. Recombinant Activated Factor VII for Adjunctive Hemorrhage Control in Trauma. *Journal of Trauma-Injury Infection & Critical Care* 2001, September; 51(3): 431-439.
118. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated Factor VII for acute intracerebral haemorrhage. *N Engl J Med* 2005; 352: 777-785.
119. McHutchison JG, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. *N Engl J Med* 2007, Nov 29; 357: 2227.
120. Mikhael J, Melosky B et al. Canadian supportive care recommendations for the management of anemia in patients with cancer. *Curr Oncol*. 2007, October; 14(5): 209-217.
121. Mirhashemi R, Averette HE, Deepika K, et al. The impact of intraoperative autologous blood transfusion during type III radical hysterectomy for early-stage cervical cancer. *Am J Obstet Gynecol* 1999; 181: 1310-1315.
122. Mock T, Morrison D, Yatscoff R. Evaluation of the i-STAT system: a portable chemistry analyzer for the measurement of sodium, potassium, chloride, urea, glucose, and hematocrit. *Clin Biochem* 1995; 28(2): 187-192.
123. Mollison PL (ed). *Blood Transfusion in Clinical medicine*. 6th edition. Oxford: Blackwell Scientific, 1979.
124. Monk TG. Preoperative recombinant human erythropoietin in anemic surgical patients. *Critical Care* 2004, 8 (Suppl 2): p. S45-S48.
125. Muñoz M, et al. Pharmacological management of perioperative anaemia: our experience in orthopedic surgery. *Vox Sanguinis* July 2007; 93(Suppl.1): 47.
126. Muñoz M. In which indication should we use IV iron instead of blood transfusion? Experience in major surgery. *Perspectives in IV iron*. *International Series of Meetings*, January 2008; 12-13.
127. Murkin J. Lessons learned in antifibrinolytic therapy: the BART trial. *Semin Cardiothorac Vasc Anesth* 2009;13:127-131.
128. Nagarsheth NP, Shander A, Malovany R, Tzeng J, Ibrahim I. Bloodless Surgery in a Jehovah's Witness Patient with a 12.7-kg Uterine Leiomyosarcoma. *J Surg Educ* 2007, Jul-Aug; 64(4): 212-219.
129. NICE technology appraisal guidance 142. Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia. National Institute for Health and Clinical Excellence. www.nice.org.uk/TA142.
130. NovoSeven® SPC, 2007, Novo Nordisk A/S.
131. Ott DA, Cooley DA. Cardiovascular Surgery in Jehovah's Witnesses. *JAMA* 1977; 1638: 1256-1258.
132. Park P, Fewel ME, Garton HJ, Thompson BG, Hoff JT. Recombinant Activated Factor VII for the Rapid Correction of Coagulopathy in Nonhemophilic Neurosurgical Patients. *Neurosurgery* 2003, July; 53(1): 34-39.
133. Pedrazzoli P, Farris A et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. *J Clin Oncol*. 2008 Apr 1;26(10):1619-1625.
134. Phillips P. Trial suggest change in transfusion strategy. *JAMA* 1998; 279(20): 1596-1597.
135. Pihusch M, et al. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. *J Thromb Haemost* 2005; 3: 1935-1944.
136. Planinsic RM, van der Meer J, Testa G, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. *Liver Transplant* 2005; 11: 895-900.

137. Popovsky MA; Chaplin HC Jr; Moore SB. Transfusion-related acute lung injury: a neglected, serious complication of hemotherapy. *Transfusion* 1992, Jul-Aug; 32(6): 589-592.
138. Porte RJ, Molenaar IQ, Begliomini B, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. *Lancet* 2000; 355(9212): 1303-1309.
139. Quan D, Wall WJ. The safety of continuous hepatic inflow occlusion during major liver resection. *Liver Transplant Surg* 1996; 2(2): 99-104.
140. Ragusa R, Faggian G, Rungatscher A, et al. Use of gelatin powder added to rifamycin versus bone wax in sternal wound hemostasis after cardiac surgery. *Interact CardioVasc Thorac Surg* 2007; 6: 52-55.
141. Rees M, Plant G, Wells J, et al. One hundred fifty hepatic resections: evaluation of technique towards bloodless surgery. *Br J Surg* 1997; 83(11): 1526-1529.
142. Reynolds JD et al. S-nitrosohemoglobin deficiency: A mechanism for loss of physiological activity in banked blood, *Proc Natl Acad sci* 2007; 104: 17058-17062.
143. Rinsch C, Regulier E, Deglon N, et al. A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. *Hum Gene Ther* 1997; 8(16): p. 1881-1889.
144. Rivera S, Liu L, Nemeth E, et al. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. *Blood*. 2005; 105: 1797-1802.
145. Rizzo JD, Somerfield MR et al. American Society of Hematology/American Society of Clinical Oncology 2007 clinical practice guideline update on the use of epoetin and darbepoetin. *Blood*, 1 January 2008, Vol. 111, No. 1, pp. 25-41.
146. Rosengart TK, et al. Open heart operations without transfusion using a multimodality blood conservation strategy in 50 Jehovah's Witness patients: implications for a »bloodless« surgical technique. *J Am Coll Surg* 1997; 184: 618-629.
147. Rudmann, SV. Textbook of blood banking and transfusion medicine. Second Edition. Philadelphia: Elsevier Saunders, 2005, 376.
148. Sabel M, Stummer W. The use of local agents: Surgicel and Surgifoam. *Eur Spine J* 2004; 13 (Suppl. 1): S97-S101.
149. Salido JA, Marín LA, Gómez LA, et al. Pre-operative hemoglobin levels and the need for transfusion after prosthetic hip and knee surgery: analysis of predictive factors. *J Bone Joint Surg Am*. 2002; 84-A(2): p. 216-220.
150. Scott BH, Seifert FC, Grimson R. Blood transfusion is associated with increased resource utilisation, morbidity and mortality in cardiac surgery. *Ann Card Anaesth* 2008; 11(1): 15-19.
151. Seto AH, Dunlap DS. Tranexemic acid in oncology. *Ann Pharmacother Surg* 1996; 30(7-8): 868-870.
152. Shapiro AD, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. *J Thromb Haemost* 1998; 80: 773-778.
153. Sharma JB, Malhotra M, Pundir P. Laparoscopic oxidized cellulose (Surgicel) application for small uterine perforations. *Int J Gynaecol Obstet* 2003; 83: 271-275.
154. Sharma S, Nemeth E et al. Involvement of hepcidin in the anemia of multiple myeloma. *Clin Cancer Res*. 2008 Jun 1;14(11):3262-3267.
155. Shibata T, Murakami T, Ogata N. Percutaneous microwave coagulation therapy for patients with primary and metastatic hepatic tumors during interruption of hepatic blood flow. *Cancer* 2000; 88(2): 302-311.
156. Shord SS, Cuellar S. Chemotherapy-induced anemia at an urban academic medical center: iron studies and supplementation. *J Am Pharm Assoc* (2003). 2008 Jul-Aug; 48(4): 487-493.
157. Schmied H, Kurz A, Sessler DI, et al. Mild hypothermia increases blood loss and transfusion requirements during total hip arthroplasty. *Lancet* 1996; 347(1997): 289-292.
158. Silliman CC, Paterson AJ, Dickey WO, Strock DF, Popovsky MA, Caldwell SA, Ambroso DR. The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study. *Transfusion* 1997, Jul; 37(7): 719-726.
159. Silver M, Bazan A, Corwin HL, et al. A randomized double blind placebo controlled trial of recombinant human erythropoietin in long-term acute care patients. *Crit Care Med* 2006; 34: 2310-2316.
160. Slotman GJ, Stein SC. Laparoscopic L5-S1 discectomy. A cost-effective, minimally invasive general surgery-neurosurgery team alternative to laminectomy. *Am Surg* 1996; 62(1): 64-68.
161. Smoller BR, Kruskall MS, Horowitz GL. Reducing adult phlebotomy blood loss with the use of pediatric-sized blood collection tubes. *Am J Clin Pathol* 1997; 91(6): 701-703.
162. Spangler D, Rothenburger S, Nguyen K, et al. In vitro antimicrobial activity of oxidized regenerated cellulose against antibiotic-resistant microorganisms. *Surg Infect*, 2003; 4(3): 255-262.

163. Spence RK, Cernaianu AC, Carson J, et al. Transfusion and surgery. *Curr Probl Surg* 1993; 30(12): 1103-1180.
164. Spence RK. The status of bloodless surgery. *Transf Med Rev* 1991; 5(4): 274-286.
165. Spivak JL. The mechanism of action of erythropoietin. *Int J Cell Cloning* 1986; 4: p. 139-166.
166. Svensson EC, Black HB, Dugger DL, et al. Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector. *Hum Gene Ther* 1997; 8(15): 1797-1806.
167. Šafařík L, Novák K, Dvořáček J, Vik V. Inovativní techniky při laparoskopické parciální resekcii ledviny pro adenokarcinom. *Rozhl. Chir.* 2006; 85(7): 350-353.
168. Šegota Ivan, Sorta-Bilajac Iva. Bioethics and the Demands of Jehovah's Witnesses for Bloodless Treatment. *Journal of Japan Society for Clinical Anesthesia* 2006; 26(3): 315-320.
169. Šegota, Ivan i sur. Bioetika i zahtjevi za beskrvno liječenje. (u): Šegota, I. (ur.): Bioetika i pitanje odbijanja transfuzije krvi (zbornik radova). Medicinski fakultet Sveučilišta u Rijeci; Hrvatsko bioetičko društvo, 2001: 15-23.
170. Šegota, Ivan. Etički komiteti i bioetika, *Bioetički svesci* 1999, br.4. i br.7.
171. Takahashi K. ABO-incompatibile kidney transplantation. Amsterdam; New York, Elsevier 2001.
172. Tannahill R. *Flesh and Blood*. Boston, Massachusetts, U.S.A. Little Brown 1997.
173. Tereul JL, Marcen R, Navarro-Antolin J, et al. Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: a prospective study. *J Am Soc Nephrol* 1996; 7(1): 140-144.
174. The Journal of the American Medical Association. 1968, February 5; 399. 1966, September 5; 794-795. 1967, July 5; 150. 1967, June 5; 160.
175. Theusinger OM, et al. Treatment of iron deficiency anemia in orthopedic surgery with intravenous iron: Efficacy and limits: A prospective study. *Anesthesiology* 2007; 107: 923-927.
176. Third European Consensus Conference in Intensive Care Medicine (European Society of Intensive Care Medicine, Société de Réanimation de Langue française, The American Thoracic Society). Tissue hypoxia: how to detect, how to correct, how to prevent? *Am J Respir Crit Care Med* 1996; 154(5): 1573-1578.
177. Thomas JM. The treatment of obstetric haemorrhage in women who refuse blood transfusion. *Br J Obstet Gynaecol* 1998; 105(1): 127-128.
178. Thomas JM. The Worldwide Need for Education in Nonblood Management in Obstetric and Gynecology. *J Soc Obstet Gynaecol Can* 1994; 16(3): 1483-1487.
179. Timmouth AT, McIntyre LA, Fowler RA. Blood conservation strategies to reduce the need for red blood cell transfusion in critically ill patients. *CMAJ* 2008, Jan 1; 178(1): 49-57.
180. Tran NK, Kost GJ. Worldwide point-of-care testing: compendiums of POCT for mobile, emergency, critical, and primary care and of infectious diseases tests. *Point of Care: The Journal of Near-Patient Testing & Technology* 2006; 5: 84-92.
181. Trojan Stanislav a kol: *Lékařská fyziologie*. 4. přeprac. a dopl. Praha: Grada, 2004.
182. Tuman KJ. Tissue oxygen delivery: the physiology of anemia. *Anesthesiol Clin North Am* 1990 Sep; 8(3): 451-469.
183. University of Bristol. Red Blood Cell Transfusions Could Increase Risk Of Heart Attack Or Stroke. *Science Daily* 2007, November 28.
184. Vadhan-Raj S, Mzrray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in a patients with cancer. *Ann Intern Med* 1997; 126(9): 673-681.
185. Vadhan-Raj S. Recombinant human erythropoietin in combination with other hematopoietic cytokines in attenuating chemotherapy-induced multilineage myelosuppression: brief communication. *Semin Hematol* 1996; 18(1, Suppl 1): 16-18.
186. Vamvakas EC, Blajchman MA: Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. *Blood*. 2009 Apr 9; 113(15): 3406-3417.
187. Van Straten AH, Bekker MW et al. Transfusion of red blood cells: the impact on short-term and long-term survival after coronary artery bypass grafting, a ten-year follow-up. *Interact Cardiovasc Thorac Surg*. 2010 Jan; 10(1): 37-42.
188. Vaněk T, Špegár J, Šnircová J. Antifi brinolytika v kardiochirurgii - pohled z konce prvního desetiletí nového milénia. *Cor Vasa* 2010; 52(Suppl 1): 48-51.
189. Vick LR, Islam S. Recombinant factor VIIa as an adjunct in nonoperative management of solid organ injuries in children. *J Pediatr Surg* 2008; 43(1): 195-199.
190. Vidarsson B, Onundarson PT. Recombinant factor VIIa for bleeding in refractory throm-

- bocytopenia. *J Thromb Haemost* 2000; 83: 634-635.
191. Vincent JL, Rossaint R, Riou B, et al. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding - a European perspective. *Crit Care* 2006; 10: r120.
 192. Warren O, et al. Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review. *Ann Thorac Surg* 2007; 83: 707-714.
 193. Weiss G, Goodnough LT. Anemia of chronic disease. *N Engl J Med* 2005; 352: 43-55.
 194. Whit GC, Marder VJ, Colman RW et al. Approach to the bleeding patient. In: Colman RW, Hirsh J, Marder VJ, et al. *Hemostasis and Thrombosis. Basic principles and Clinic Practice*. 3rd ed. Philadelphia: Lippincott 1994; 1134-1147.
 195. White B, McHale J, Ravi N, Reynolds J, Stephens R, Moriarty J, Smith OP: Successful use of recombinant FVIIa (NovoSeven®) in the management of intractable post-surgical intra-abdominal haemorrhage. *Br J Haematol* 1999; 107: 677-678.
 196. Willmann PA, Dean A: Retrospective Review of Total-Dose Iron Dextran in Iron-Deficiency Anemia of Chronic Disease and Relevance to Blood Transfusion Requirements: An Individual Institution Experience. 50th Annual Meeting of American Society of Hematology, December 6-9, 2008, San Francisco, Poster Nu. 2876.
 197. World Medical Association. Declaration of Ottawa on The right of the child to health care. *Bull. Med Ethics* 1999, February.
 198. Zbornik radova, Simpozij Beskrvno liječenje medicinski, etički i pravni aspekti, Sarajevo, Bosna i Hercegovina, 15. novembar 2001.
 199. Zhou XD, Tang ZY, Yu YQ et al. Microwave surgery in the treatment of hepatocellular carcinoma. *Semin Surg Oncol* 1997; 9(4): 318-322.
 200. Život ohrožující krvácení - doporučený postup, konsenzuální stanovisko. *Úraz. chir.* 2007; 15(1).